» Articles » PMID: 20952464

Increased Prevalence of Metabolic Syndrome Associated with Rheumatoid Arthritis in Patients Without Clinical Cardiovascular Disease

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2010 Oct 19
PMID 20952464
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: to examine whether patients with rheumatoid arthritis (RA) with no overt cardiovascular disease (CVD) have a higher prevalence of metabolic syndrome (MetS) than subjects without RA or CVD. We also examined whether RA disease characteristics are associated with the presence of MetS in RA patients without CVD.

Methods: subjects from a population-based cohort of patients who fulfilled 1987 American College of Rheumatology criteria for RA between January 1, 1980, and December 31, 2007, were compared to non-RA subjects from the same population. All subjects with any history of CVD were excluded. Waist circumference, body mass index (BMI), and blood pressure were measured during the study visit. Data on CVD, lipids, and glucose measures were ascertained from medical records. MetS was defined using NCEP/ATP III criteria. Differences between the 2 cohorts were examined using logistic regression models adjusted for age and sex.

Results: the study included 232 RA subjects without CVD and 1241 non-RA subjects without CVD. RA patients were significantly more likely to have increased waist circumference and elevated blood pressure than non-RA subjects, even though BMI was similar in both groups. Significantly more RA patients were classified as having MetS. In RA patients, MetS was associated with Health Assessment Questionnaire Disability Index, large-joint swelling, and uric acid levels, but not with C-reactive protein or RA therapies.

Conclusion: among subjects with no history of CVD, patients with RA are more likely to have MetS than non-RA subjects. MetS in patients with RA was associated with some measures of disease activity.

Citing Articles

Prevalence of Metabolic Syndrome in Patients With Rheumatoid Arthritis: An Updated Systematic Review and Meta-Analysis.

Cai W, Tang X, Pang M Front Med (Lausanne). 2022; 9:855141.

PMID: 35462993 PMC: 9024100. DOI: 10.3389/fmed.2022.855141.


Prevalence of Metabolic Syndrome in Treatment Naïve Rheumatoid Arthritis and Correlation With Disease Parameters.

Pandey P, Swami A, Biswas T, Thakuria R Arch Rheumatol. 2018; 32(1):46-52.

PMID: 30375525 PMC: 6190937. DOI: 10.5606/ArchRheumatol.2017.5949.


Metabolic syndrome in adults with a history of juvenile arthritis.

Sule S, Fontaine K Open Access Rheumatol. 2018; 10:67-72.

PMID: 29922101 PMC: 5995292. DOI: 10.2147/OARRR.S157229.


Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients.

Peluso R, Caso F, Tasso M, Ambrosino P, Di Minno M, Lupoli R Rev Recent Clin Trials. 2018; 13(3):199-209.

PMID: 29542417 PMC: 6691775. DOI: 10.2174/1574887113666180314105511.


Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial: protocol for a cohort study with patient-record evaluated outcomes.

Herly M, Stengaard-Pedersen K, Horslev-Petersen K, Hetland M, Ostergaard M, Christensen R BMJ Open. 2017; 7(4):e014816.

PMID: 28391237 PMC: 5541299. DOI: 10.1136/bmjopen-2016-014816.


References
1.
Pereira R, de Carvalho J, Bonfa E . Metabolic syndrome in rheumatological diseases. Autoimmun Rev. 2009; 8(5):415-9. DOI: 10.1016/j.autrev.2009.01.001. View

2.
Galassi A, Reynolds K, He J . Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006; 119(10):812-9. DOI: 10.1016/j.amjmed.2006.02.031. View

3.
Wasko M, Hubert H, Lingala V, Elliott J, Luggen M, Fries J . Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007; 298(2):187-93. DOI: 10.1001/jama.298.2.187. View

4.
Sidiropoulos P, Karvounaris S, Boumpas D . Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther. 2008; 10(3):207. PMC: 2483433. DOI: 10.1186/ar2397. View

5.
. Screening adults for lipid disorders: recommendations and rationale. Am J Prev Med. 2001; 20(3 Suppl):73-6. View